Personensuche
Personensuche
Es wurde 1 Person gefunden.
Telefon
Webseite
Funktionen
-
Direktor/in, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
-
2024 WS
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
- Vorlesung des GRK 1739 (mit Gastsprechern)
- Endokrines Tumorzentrum am WTZ und ENETS-Center of Excellence
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Integriertes Seminar klinische Untersuchungen (1. Abschnitt der Ärztlichen Ausbildung) (nur Wintersemester) (PV)
- Hämatologisches und onkologisches Mittagsseminar
- Differentialdiagnose Innere Krankheiten
- Blockpraktikum Innere Medizin (PV)
- Öffentliches Tumorboard Lungenkrebszentrum
- Molekulare Onkologie
- Arbeiten in den Laboratorien der Inneren Klinik (Tumorforschung)
- Innere Medizin für Studierende im Praktischen Jahr (*)
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Endokrines Tumorzentrum am WTZ und ENETS-Center of Excellence
- Vorlesung des GRK 1739 (mit Gastsprechern)
- Innere Medizin Vorlesung, Teil 1 (WA)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
- Wahlpflichtmodul Innere Medizin (Studiengang Med. Biologie)
- Hämatologisches und onkologisches Mittagsseminar
- Molekulare Onkologie
- Öffentliches Tumorboard Lungenkrebszentrum
- Blockpraktikum Innere Medizin (PV)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 880 - 887Online Volltext: dx.doi.org/
-
Aktuelle Standards und vielversprechende Innovationen in der medikamentösen Zweitlinientherapie des metastasierten kleinzelligen Lungenkarzinoms (ED-SCLC)In: Die Onkologie Jg. 30 (2024) Nr. 9, S. 809 - 816Online Volltext: dx.doi.org/
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease : a secondary analysis from MARIPOSAIn: Annals of Oncology Jg. 35 (2024) Nr. 9, S. 805 - 816Online Volltext: dx.doi.org/ (Open Access)
-
Applicability of a digital health application for cancer patients : A qualitative non-participation analysisIn: BMC Health Services Research Jg. 24 (2024) Nr. 1, 1187Online Volltext: dx.doi.org/ (Open Access)
-
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapyIn: Scientific Reports Jg. 14 (2024) Nr. 1, 13765Online Volltext: dx.doi.org/ (Open Access)
-
Closing the RCT Gap : A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer PatientsIn: Cancers Jg. 16 (2024) Nr. 11, 2078Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapiesIn: European Journal of Cancer (EJC) Jg. 200 (2024) 113540Online Volltext: dx.doi.org/ (Open Access)
-
Drivers and barriers of patients’ acceptance of video consultation in cancer careIn: Digital Health Jg. 10 (2024)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired ResistanceIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 851 - 855Online Volltext: dx.doi.org/
-
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole : Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerIn: European Journal of Cancer (EJC) Jg. 198 (2024) 113480Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany : A historical cohort analysisIn: The Lancet Regional Health - Europe Jg. 36 (2024) 100788Online Volltext: dx.doi.org/ (Open Access)
-
Evolutionary trajectories of small cell lung cancer under therapyIn: Nature Jg. 627 (2024) Nr. 8005, S. 880 - 889Online Volltext: dx.doi.org/ (Open Access)
-
Exploring the impact of durvalumab on biliary tract cancer : insights from real-world clinical dataIn: Cancer Immunology, Immunotherapy Jg. 73 (2024) Nr. 12, S. 251Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 2, S. 252 - 257Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1188 - 1193Online Volltext: dx.doi.org/
-
From admission to discharge : A systematic review of clinical natural language processing along the patient journeyIn: BMC Medical Informatics and Decision Making Jg. 24 (2024) Nr. 1, 238Online Volltext: dx.doi.org/ (Open Access)
-
Investigation of screening questions to identify insomnia in cancer patientsIn: Scientific Reports Jg. 14 (2024) Nr. 1, 18343Online Volltext: dx.doi.org/ (Open Access)
-
LIONS PREY : A New Logistic Scoring System for the Prediction of Malignant Pulmonary NodulesIn: Cancers Jg. 16 (2024) Nr. 4, 729Online Volltext: dx.doi.org/ (Open Access)
-
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment : Comparison with Stage III DiseaseIn: Cancers Jg. 16 (2024) Nr. 6, 1174Online Volltext: dx.doi.org/ (Open Access)
-
Long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer : Plain language summaryIn: Future Oncology Jg. 20 (2024) Nr. 3, S. 113 - 120Online Volltext: dx.doi.org/ (Open Access)
-
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer : A randomized phase 2 trialIn: Nature Medicine Jg. 30 (2024) Nr. 6, S. 1602 - 1611Online Volltext: dx.doi.org/ (Open Access)
-
Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer PatientsIn: Clinical EEG and Neuroscience (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Oligometastatic non-small cell lung cancer : Impact of local and contemporary systemic treatment approaches on clinical outcomeIn: International Journal of Cancer (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
P-move : A randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapyIn: Supportive Care in Cancer Jg. 32 (2024) Nr. 7, 437Online Volltext: dx.doi.org/ (Open Access)
-
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 210 (2024) 114268Online Volltext: dx.doi.org/ (Open Access)
-
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer PatientsIn: Cancers Jg. 16 (2024) Nr. 2, 465Online Volltext: dx.doi.org/ (Open Access)
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer : Updated Efficacy and Safety Data from the ARROW StudyIn: Thyroid Jg. 34 (2024) Nr. 1, S. 26 - 40Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanomaIn: Pigment Cell and Melanoma Research Jg. 37 (2024) Nr. 6, S. 831 - 838Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer : A retrospective multicenter studyIn: ESMO Open Jg. 9 (2024) Nr. 1, 102219Online Volltext: dx.doi.org/ (Open Access)
-
Relevance of Patient-Reported Outcome Measures in Patients with Cancer : Detection of Underrated Psychological Distress of Palliative Care Patients in an Outpatient SettingIn: Palliative Medicine Reports Jg. 5 (2024) Nr. 1, S. 194 - 200Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)In: International Journal of Cancer (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics Jg. 14 (2024) Nr. 14, S. 5400 - 5412Online Volltext: dx.doi.org/ (Open Access)
-
Understanding homologous recombination repair deficiency in biliary tract cancers : clinical implications and correlation with platinum sensitivityIn: ESMO Open Jg. 9 (2024) Nr. 8, 103630Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 10, S. 1540 - 1549Online Volltext: dx.doi.org/ (Open Access)
-
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)In: Oncology Research and Treatment Jg. 46 (2023) Nr. 3, S. 89 - 99Online Volltext: dx.doi.org/
-
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 5085 - 5094Online Volltext: dx.doi.org/ (Open Access)
-
Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy : A Clinical Waitlist Control StudyIn: Applied Psychophysiology Biofeedback Jg. 48 (2023) Nr. 2, S. 217 - 227Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsIn: Oncology Research and Treatment Jg. 46 (2023) Nr. 4, S. 140 - 150Online Volltext: dx.doi.org/
-
Deep learning-based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancerIn: Journal of Cachexia, Sarcopenia and Muscle Jg. 14 (2023) Nr. 1, S. 545 - 552Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Early Detection of Lung Cancer Using Small RNAsIn: Journal of Thoracic Oncology Jg. 18 (2023) Nr. 11, S. 1504 - 1523Online Volltext: dx.doi.org/ (Open Access)
-
Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological InpatientsIn: Cancers Jg. 15 (2023) Nr. 11, 3029Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR) : An international, single-arm, phase 2 studyIn: The Lancet Oncology Jg. 24 (2023) Nr. 8, S. 925 - 935Online Volltext: dx.doi.org/
-
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 11, S. 9243 - 9252Online Volltext: dx.doi.org/ (Open Access)
-
HPV-associated head and neck cancer is characterized by distinct profiles of CD8⁺ T cells and myeloid-derived suppressor cellsIn: Cancer Immunology, Immunotherapy Jg. 72 (2023) S. 4367 - 4383Online Volltext: dx.doi.org/ (Open Access)
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 4315 - 4325Online Volltext: dx.doi.org/ (Open Access)
-
Impact of encorafenib on survival of patients with BRAFV⁶⁰⁰E-mutant metastatic colorectal cancer in a real-world settingIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 14, S. 12903 - 12912Online Volltext: dx.doi.org/ (Open Access)
-
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesotheliomaIn: Lung Cancer Jg. 185 (2023) 107360Online Volltext: dx.doi.org/
-
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer : 2-Year Analysis of CodeBreaK 100In: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 18, S. 3311 - 3317Online Volltext: dx.doi.org/ (Open Access)
-
Molecular Imaging Biomarkers in Cardiooncology : A View on Established Technologies and Future PerspectivesIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 2, S. 29S - 38SOnline Volltext: dx.doi.org/ (Open Access)
-
Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients : Results of an Explorative Randomized Controlled TrialIn: Integrative Cancer Therapies Jg. 22 (2023)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung MetastasesIn: Cancers Jg. 15 (2023) Nr. 17, 4355Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Personalized Treatment for Patients With Lung CancerIn: Deutsches Ärzteblatt international Jg. 120 (2023) Nr. 17, S. 300 - 310Online Volltext: dx.doi.org/ (Open Access)
-
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 16, S. 2869 - 2876Online Volltext: dx.doi.org/
-
Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases : A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic FactorsIn: Current Oncology Jg. 30 (2023) Nr. 11, S. 9458 - 9474Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Preoperative PET-SUVmax and volume based PET parameters of the primary tumor fail to predict nodal upstaging in early-stage lung cancerIn: Lung Cancer Jg. 176 (2023) S. 82 - 88Online Volltext: dx.doi.org/
-
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication PlatformIn: European Journal of Epidemiology Jg. 38 (2023) Nr. 5, S. 573 - 586Online Volltext: dx.doi.org/ (Open Access)
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 8, S. 1191 - 1194Online Volltext: dx.doi.org/ (Open Access)
-
Smaller panel, similar results : Genomic profiling and molecularly informed therapy in pancreatic cancerIn: ESMO Open Jg. 8 (2023) Nr. 3, 101539Online Volltext: dx.doi.org/ (Open Access)
-
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic CancerIn: The New England Journal of Medicine Jg. 388 (2023) Nr. 1, S. 33 - 43Online Volltext: dx.doi.org/ (Open Access)
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG¹²C mutation : a randomised, open-label, phase 3 trialIn: Lancet Jg. 401 (2023) Nr. 10378, S. 733 - 746Online Volltext: dx.doi.org/
-
TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapyIn: Lung Cancer Jg. 178 (2023) S. 237 - 246Online Volltext: dx.doi.org/
-
The INFINITY study protocol : A retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practiceIn: BMC Cancer Jg. 23 (2023) Nr. 1, 543Online Volltext: dx.doi.org/ (Open Access)
-
The OUTREACH study: Oncologists of German university hospitals in rotation on a palliative care unit : Evaluation of attitude and competence in palliative care and hospiceIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 7, S. 2929 - 2936Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 1, S. 89 - 95Online Volltext: dx.doi.org/ (Open Access)
-
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsIn: Journal of Experimental & Clinical Cancer Research Jg. 41 (2022) Nr. 1, 189Online Volltext: dx.doi.org/ (Open Access)
-
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations : An Updated Database of 1023 Cases Brief ReportIn: Frontiers in Oncology Jg. 12 (2022) 834704Online Volltext: dx.doi.org/ (Open Access)
-
Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancerIn: Translational Oncology Jg. 15 (2022) Nr. 1, 101279Online Volltext: dx.doi.org/ (Open Access)
-
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapyIn: BMC Cancer Jg. 22 (2022) Nr. 1, 46Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer : focus on treatment selection and prognostic factorsIn: Immunotherapy Jg. 14 (2022) Nr. 12, S. 927 - 944Online Volltext: dx.doi.org/ (Open Access)
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 727 - 734Online Volltext: dx.doi.org/ (Open Access)
-
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatmentIn: Radiation Oncology Jg. 17 (2022) Nr. 1, 126Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Multimodal survival prediction in advanced pancreatic cancer using machine learningIn: ESMO Open Jg. 7 (2022) Nr. 5, 100555Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PARPACT – Paramedic Palliative Care Test : Validierung eines Tests für palliatives Wissen und Selbstwirksamkeitserwartung bei Mitarbeiter*innen im RettungswesenIn: Der Schmerz Jg. 36 (2022) Nr. 5, S. 333 - 341Online Volltext: dx.doi.org/ (Open Access)
-
Palliative care outpatients in a German comprehensive cancer center : identifying indicators for early and late referralIn: BMC Palliative Care Jg. 21 (2022) Nr. 1, 221Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trialIn: Nature Medicine Jg. 28 (2022) Nr. 8, S. 1640 - 1645Online Volltext: dx.doi.org/ (Open Access)
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaIn: Clinical Cancer Research Jg. 28 (2022) Nr. 14, S. 3002 - 3010Online Volltext: dx.doi.org/ (Open Access)
-
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With CancerIn: JAMA Oncology Jg. 8 (2022) Nr. 12, S. 1830 - 1839Online Volltext: dx.doi.org/
-
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CTIn: Scientific Reports Jg. 12 (2022) Nr. 1, 17511Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsIn: Lung Cancer Jg. 168 (2022) S. 10 - 20Online Volltext: dx.doi.org/
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4346 - 4353Online Volltext: dx.doi.org/ (Open Access)
-
Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancerIn: Cell Death and Disease Jg. 13 (2022) Nr. 6, 529Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The clinical utility of cfRNA for disease detection and surveillance : A proof of concept study in non-small cell lung cancerIn: Thoracic Cancer (2022) in pressOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen LungenkarzinomsIn: Die Innere Medizin Jg. 63 (2022) Nr. 7, S. 717 - 723Online Volltext: dx.doi.org/
-
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer : findings from the RIBECCA trialIn: European Journal of Cancer (EJC) Jg. 162 (2022) S. 45 - 55Online Volltext: dx.doi.org/
-
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerIn: Therapeutic Advances in Medical Oncology Jg. 13 (2021)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V⁶⁰⁰-mutated Squamous Cell Lung Cancer : Concurrent Evolvement of PTEN and MEK1 MutationsIn: Clinical Lung Cancer Jg. 22 (2021) Nr. 5, S. E668 - E672Online Volltext: dx.doi.org/
-
Antitumor immune response is associated with favorable survival in GEP-NEN G3In: Endocrine-Related Cancer Jg. 28 (2021) Nr. 10, S. 683 - 693Online Volltext: dx.doi.org/
-
Assessment of coronary artery disease during hospitalization for cancer treatmentIn: Clinical Research in Cardiology Jg. 110 (2021) Nr. 2, S. 200 - 210Online Volltext: dx.doi.org/ (Open Access)
-
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 211 - 221Online Volltext: dx.doi.org/
-
Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months : A comparative studyIn: Supportive Care in Cancer Jg. 29 (2021) Nr. 9, S. 5127 - 5137Online Volltext: dx.doi.org/ (Open Access)
-
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 2, S. 579 - 591Online Volltext: dx.doi.org/ (Open Access)
-
Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyIn: The Pharmacogenomics Journal Jg. 21 (2021) Nr. 2, S. 273Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”In: Annals of Oncology Jg. 32 (2021) Nr. 1, S. 126Online Volltext: dx.doi.org/ (Open Access)
-
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyIn: The Pharmacogenomics Journal Jg. 21 (2021) Nr. 1, S. 37 - 46Online Volltext: dx.doi.org/ (Open Access)
-
FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaIn: Annals of Oncology Jg. 32 (2021) Nr. 5, S. 609 - 619Online Volltext: dx.doi.org/ (Open Access)
-
GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancerIn: Cancer Research Jg. 81 (2021) Nr. 11, S. 2970 - 2982Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
HER2 mediates clinical resistance to the KRASG¹²C inhibitor sotorasib, which is overcome by co-targeting SHP2In: European Journal of Cancer (EJC) Jg. 159 (2021) S. 16 - 23Online Volltext: dx.doi.org/
-
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including CetuximabIn: Frontiers in Oncology Jg. 11 (2021) 635096Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLCIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) S. 2894 - 2903Online Volltext: dx.doi.org/ (Open Access)
-
Lung Cancer Surgery after Neoadjuvant ImmunotherapyIn: Cancers Jg. 13 (2021) Nr. 16, 4033Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon MutationsIn: Journal of Thoracic Oncology Jg. 16 (2021) Nr. 1, S. 31Online Volltext: dx.doi.org/ (Open Access)
-
N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standardIn: EJNMMI Research Jg. 11 (2021) Nr. 1, 68Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Patterns of nodal spread in stage III NSCLC : Importance of EBUS-TBNA and ¹⁸F-FDG PET/CT for radiotherapy target volume definitionIn: Radiation Oncology Jg. 16 (2021) Nr. 1, 176Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumorsIn: Clinical Cancer Research Jg. 27 (2021) Nr. 10, S. 2723 - 2733Online Volltext: dx.doi.org/ (Open Access)
-
Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial TumorsIn: Pathology & Oncology Research Jg. 27 (2021) S. 629993Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW) : a multi-cohort, open-label, registrational, phase 1/2 studyIn: The Lancet Diabetes and Endocrinology Jg. 9 (2021) Nr. 8, S. 491 - 501Online Volltext: dx.doi.org/
-
Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive ChemoradiotherapyIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 12, S. 1684 - 1691Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Sotorasib for Lung Cancers with KRAS p.G12C MutationIn: The New England Journal of Medicine Jg. 384 (2021) Nr. 25, S. 2371 - 2381Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Systemische Tumortherapien des CUP-SyndromsIn: Der Onkologe Jg. 27 (2021) Nr. 7, S. 658 - 662Online Volltext: dx.doi.org/
-
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations : A Database of 693 CasesIn: Journal of Thoracic Oncology Jg. 15 (2020) Nr. 5, S. 803 - 815Online Volltext: dx.doi.org/ (Open Access)
-
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionIn: Frontiers in Immunology Jg. 11 (2020) S. 1849Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX TrialIn: Clinical Colorectal Cancer Jg. 19 (2020) Nr. 4, S. 236 - 247.e6Online Volltext: dx.doi.org/
-
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expressionIn: Cancer Medicine Jg. 9 (2020) Nr. 13, S. 4527 - 4539Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutationIn: Lung Cancer Jg. 139 (2020) S. 165 - 168Online Volltext: dx.doi.org/
-
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesotheliomaIn: Histopathology Jg. 77 (2020) Nr. 1, S. 55 - 66Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment : Only few risks left to improveIn: European Journal of Cancer (EJC) Jg. 138 (2020) S. 156 - 168Online Volltext: dx.doi.org/
-
Crizotinib in ROS1 and MET deregulated NSCLC-letterIn: Clinical Cancer Research Jg. 26 (2020) Nr. 7, S. 1774Online Volltext: dx.doi.org/ (Open Access)
-
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesotheliomaIn: Lung Cancer Jg. 139 (2020) S. 124 - 132Online Volltext: dx.doi.org/
-
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancerIn: Lung Cancer Jg. 149 (2020) S. 10 - 16Online Volltext: dx.doi.org/
-
Einfluss des CDK4/6-Inhibitors Ribociclib auf die periphere Immunantwort beim Hormonrezeptor-positiven MammakarzinomIn: Geburtshilfe und Frauenheilkunde Jg. 80 (2020) Nr. 6, S. e53Online Volltext: dx.doi.org/
-
Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patientsIn: BMC Palliative Care Jg. 19 (2020) Nr. 1, S. 43Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasisIn: Oncogenesis Jg. 9 (2020) Nr. 11, S. 102Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma modelIn: Lung Cancer Jg. 144 (2020) S. 20 - 29Online Volltext: dx.doi.org/
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology (2020)Online Volltext: dx.doi.org/ (Open Access)
-
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextIn: European Journal of Cancer (EJC) Jg. 140 (2020) S. 76 - 85Online Volltext: dx.doi.org/
-
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trialIn: Annals of Oncology Jg. 31 (2020) Nr. 6, S. 789 - 797Online Volltext: dx.doi.org/ (Open Access)
-
Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohortsIn: Cancer Science Jg. 111 (2020) Nr. 2, S. 536 - 547Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsIn: The Oncologist Jg. 24 (2020) Nr. 1, S. e160 - e169Online Volltext: dx.doi.org/ (Open Access)
-
Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancerIn: Cancers Jg. 12 (2020) Nr. 2, S. 353Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyIn: The Journal of Clinical Investigation (JCI) Jg. 130 (2020) Nr. 8, S. 4266 - 4281Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The quest for efficient trial designs in precision oncologyIn: The Lancet Oncology Jg. 21 (2020) Nr. 12, S. 1539 - 1541Online Volltext: dx.doi.org/
-
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion : the impact of C-reactive protein and immune-checkpoint inhibitionIn: Scientific Reports Jg. 10 (2020) Nr. 1, S. 5784Online Volltext: dx.doi.org/ (Open Access)
-
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO studyIn: Annals of Oncology Jg. 30 (2019) Nr. 9, S. 1487 - 1495Online Volltext: dx.doi.org/ (Open Access)
-
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancersIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 6018Online Volltext: dx.doi.org/
-
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical TrialIn: JAMA Oncology Jg. 5 (2019) Nr. 2, S. e184475Online Volltext: dx.doi.org/ (Open Access)
-
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular diseaseIn: International Journal of Cardiology Jg. 280 (2019) S. 163 - 175Online Volltext: dx.doi.org/
-
Cerebral Recurrence after trimodal Therapy of Patients with locally advanced NSCLC - Prognostic Factors and prognostic ImportanceIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 195 (2019) Nr. Suppl. 1, S. S66 - S67
-
Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation : An open-label, single-arm cohort of the histology-independent VE-Basket studyIn: JCO Precision Oncology Jg. 3 (2019) S. 1 - 9Online Volltext: dx.doi.org/ (Open Access)
-
First-line afatinib for advanced EGFRm+ NSCLC : Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsIn: Lung Cancer Jg. 133 (2019) S. 10 - 19Online Volltext: dx.doi.org/ (Open Access)
-
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7) : impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionIn: Journal of Cancer Research and Clinical Oncology Jg. 145 (2019) Nr. 6, S. 1569 - 1579Online Volltext: dx.doi.org/ (Open Access)
-
German Cancer Consortium (DKTK) : A national consortium for translational cancer researchIn: Molecular Oncology Jg. 13 (2019) Nr. 3, S. 535 - 542Online Volltext: dx.doi.org/ (Open Access)
-
Impact of RAS mutation subtype on clinical outcome : A cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancerIn: Oncogene Jg. 38 (2019) Nr. 16, S. 2953 - 2966Online Volltext: dx.doi.org/
-
Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocolsIn: Journal of Cancer Research and Clinical Oncology Jg. 145 (2019) Nr. 2, S. 445 - 455Online Volltext: dx.doi.org/
-
Lymph Node Involvement and the Surgical Treatment of Thymic Epithelial and Neuroendocrine CarcinomaIn: The Annals of Thoracic Surgery Jg. 107 (2019) Nr. 6, S. 1632 - 1638Online Volltext: dx.doi.org/ (Open Access)
-
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 655 - 657Online Volltext: dx.doi.org/ (Open Access)
-
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : A randomised, phase 2/3 trialIn: Lancet Jg. 393 (2019) Nr. 10184, S. 1948 - 1957Online Volltext: dx.doi.org/
-
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules : analysis of the ESPATUE randomized phase 3 trialIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 46 (2019) Nr. 7, S. 1439 - 1447Online Volltext: dx.doi.org/
-
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion studyIn: The Lancet Oncology Jg. 20 (2019) Nr. 10, S. 1454 - 1466Online Volltext: dx.doi.org/
-
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerIn: Lung Cancer Jg. 132 (2019) S. 126 - 131Online Volltext: dx.doi.org/ (Open Access)
-
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancerIn: Mucosal Immunology Jg. 12 (2019) Nr. 4, S. 990 - 1003Online Volltext: dx.doi.org/ (Open Access)
-
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma : Updated results from the FAST trial.In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 4_Suppl, S. 16Online Volltext: dx.doi.org/
-
143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7In: Journal of Thoracic Oncology Jg. 13 (2018) Nr. 4, S. S84 - S85Online Volltext: dx.doi.org/ (Open Access)
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancerIn: European Journal of Cancer (EJC) Jg. 100 (2018) S. 17 - 26Online Volltext: dx.doi.org/ (Open Access)
-
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non–Small-Cell Lung Cancer : Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 4, S. e465 - e479Online Volltext: dx.doi.org/ (Open Access)
-
CUP syndrome : Metastatic malignancy with unknown primary tumorIn: Deutsches Ärzteblatt international Jg. 115 (2018) Nr. 10, S. 157 - 162Online Volltext: dx.doi.org/ (Open Access)
-
Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7In: Journal of Thoracic Oncology Jg. 13 (2018) Nr. 9, Suppl., S. 163Online Volltext: dx.doi.org/ (Open Access)
-
Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7In: Journal of Thoracic Oncology Jg. 13 (2018) Nr. Suppl. 9, S. 163
-
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)In: The Patient Jg. 11 (2018) Nr. 1, S. 131 - 141Online Volltext: dx.doi.org/ (Open Access)
-
Dramatic response of a PD-L1- positive advanced angiosarcoma of the scalp to pembrolizumabIn: JCO Precision Oncology Jg. 2 (2018)Online Volltext: dx.doi.org/
-
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapiesIn: Future Oncology Jg. 14 (2018) Nr. 15, S. 1477 - 1486Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first lineIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii577Online Volltext: dx.doi.org/ (Open Access)
-
Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET RegistryIn: Journal of Thoracic Oncology Jg. 13 (2018) Nr. Suppl. 10, S. 367Online Volltext: dx.doi.org/ (Open Access)
-
Investigations of Long-term Survivors with locally advanced NSCLC on Morbidity of curative Therapy - Analysis of neurocognitive EffectsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl. 1, S. 110Online Volltext: dx.doi.org/ (Open Access)
-
MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 4, S. e441 - e463Online Volltext: dx.doi.org/
-
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasIn: International Journal of Cancer Jg. 143 (2018) Nr. 7, S. 1764 - 1773Online Volltext: dx.doi.org/ (Open Access)
-
Patient-Reported-Outcome-Messung (PROM) psychosozialer Belastung und Symptome für ambulante Patienten unter kurativer oder palliativer Tumortherapie : eine retrospektive Analyse eines Comprehensive Cancer CenterIn: Der Onkologe Jg. 24 (2018) Nr. 1, S. 69 - 75Online Volltext: dx.doi.org/
-
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancerIn: Cancer Chemotherapy and Pharmacology Jg. 82 (2018) Nr. 2, S. 285 - 298Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Phosphatidylinositol 3-kinase a–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors : Results from the first-in-human studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 13, S. 1291 - 1299Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal CancerIn: Clinical Colorectal Cancer Jg. 17 (2018) Nr. 2, S. e331 - e352Online Volltext: dx.doi.org/
-
Pre-therapeutic metabolic Tumor Volume (MTV) in (18) F-FDG-PET/CT as a prognostic Factor in Patients with Stage IIIA-IIIB NSCLC before Trimodal Therapy or definitive Chemoradiotherapy - Results of Phase 3 StudyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl.1, S. S41 - S42Online Volltext: dx.doi.org/ (Open Access)
-
Predictors of outpatients’ request for palliative care service at a medical oncology clinic of a German comprehensive cancer centerIn: Supportive Care in Cancer Jg. 26 (2018) Nr. 10, S. 3641 - 3647Online Volltext: dx.doi.org/
-
Pretreatment metabolic volume in PET : Prognostic in lung cancer? German ESPATUE randomised phase3trialIn: Radiotherapy and Oncology (The Green Journal) Jg. 127 (2018) Nr. Suppl.1, S. S253 - S254Online Volltext: dx.doi.org/ (Open Access)
-
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung AdenocarcinomaIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 6, S. e879 - e884Online Volltext: dx.doi.org/
-
Sequential Dose Escalation Study NEOAHA for locally advanced NSCLC - Phase I-Results of Stage 1 (Integrated Boost-Radiation in neoadjuvant Therapy)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl. 1, S. S23 - S24Online Volltext: dx.doi.org/ (Open Access)
-
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 studyIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancerIn: Cancer Discovery Jg. 7 (2017) Nr. 6, S. 610 - 619Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
CheckpointinhibitorenIn: Der Onkologe Jg. 23 (2017) Nr. 8, S. 619 - 625Online Volltext: dx.doi.org/
-
Comprehensive biomarker analyses in patients with advanced or metastatic non-small cell lung cancer prospectively treated with the polo-like Kinase 1 Inhibitor BI2536In: Oncology Research and Treatment Jg. 40 (2017) Nr. 7-8, S. 435 - 439Online Volltext: dx.doi.org/
-
Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 143 (2017) Nr. 9, S. 1733 - 1744Online Volltext: dx.doi.org/
-
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients : analysis of LUX-Lung 3 and 6In: British Journal of Cancer (BJC) Jg. 116 (2017) Nr. 2, S. 175 - 185Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors : Results of a global phase I, dose-escalation and dose-expansion studyIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 2, S. 157 - 165Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers : Results from the FAST studyIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) S. 4038 - 4038Online Volltext: dx.doi.org/
-
First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC : analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trialsIn: European Journal of Cancer (EJC) Jg. 72 1 (2017) S. 176 - S177Online Volltext: dx.doi.org/
-
First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trialsIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 2,
-
First-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) : analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trialsIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 172Online Volltext: dx.doi.org/
-
Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinibIn: European Journal of Cancer (EJC) Jg. 72 1 (2017) S. 183 - S184Online Volltext: dx.doi.org/
-
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trialIn: Annals of Oncology Jg. 28 (2017) Nr. 5, S. 1084 - 1089Online Volltext: dx.doi.org/ (Open Access)
-
Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer : efficacy, safety and prognostic parametersIn: Journal of Cancer Research and Clinical Oncology Jg. 143 (2017) Nr. 10, S. 2131 - 2141Online Volltext: dx.doi.org/
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, S. 54 - 64Online Volltext: dx.doi.org/ (Open Access)
-
Inactivation of Capicua drives cancer metastasisIn: Nature Genetics Jg. 49 (2017) Nr. 1, S. 87 - 96Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Modulation of Biomarker Expression by Osimertinib : Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I TrialIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 10, S. 1588 - 1594Online Volltext: dx.doi.org/
-
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapyIn: OncoTarget Jg. 8 (2017) Nr. 28, S. 45898 - 45917Online Volltext: dx.doi.org/ (Open Access)
-
Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO) : a randoIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 200 - 201Online Volltext: dx.doi.org/
-
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO) : A multicenter, randomized phase 3 trialIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 15_suppl, 4004Online Volltext: dx.doi.org/
-
Phase I/II study of FGF401 in adult patients (pts) with hepatocellular carcinoma (HCC) or solid tumors and positive FGFR4/KLB expressionIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 234 - 235Online Volltext: dx.doi.org/
-
RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozoleIn: Cancer Research Jg. 77 (2017) Nr. 4, S. OT2 - 01Online Volltext: dx.doi.org/
-
Randomised Phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3)In: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 170Online Volltext: dx.doi.org/
-
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung AdenocarcinomaIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. Suppl. 1, S. S1201 - S1201
-
STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 15, S. 9511Online Volltext: dx.doi.org/
-
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Jg. 8 (2017) S. 14447Online Volltext: dx.doi.org/ (Open Access)
-
Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,Online Volltext: dx.doi.org/
-
1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)In: Annals of Oncology Jg. 27 (2016) Nr. Supplement 6, S. vi427Online Volltext: dx.doi.org/
-
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trialIn: The Lancet Oncology Jg. 17 (2016) Nr. 4, S. 452 - 463Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged >=65 Years : Subgroup Analysis of LUX-Lung 3/6: P1.33: Track: Advanced NSCLCIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 10 Supplement, S. 202 - S.203Online Volltext: dx.doi.org/ (Open Access)
-
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trialIn: Annals of Oncology Jg. 27 (2016) Nr. 3, S. 417 - 423Online Volltext: dx.doi.org/ (Open Access)
-
Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trialIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl.6, S. 508POnline Volltext: dx.doi.org/
-
Circulating Tumor Cell Composition in Renal Cell CarcinomaIn: PLoS ONE Jg. 11 (2016) Nr. 4, e0153018Online Volltext: dx.doi.org/ (Open Access)
-
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsIn: Journal of Cancer Research and Clinical Oncology Jg. 142 (2016) Nr. 4, S. 795 - 805Online Volltext: dx.doi.org/
-
Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 resultsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 2, S. ii127 - ii128Online Volltext: dx.doi.org/
-
Concluding remarks : [Korrespondenz zu "Lung Cancer Screening Using Low Dose CT Scanning in Germany by Prof. Dr. med. Andreas Stang, MPH, Prof. Dr. med. Martin Schuler, Dr. rer. nat. Dr. rer. san. Bernd Kowall, Dr. med. Kaid Darwiche, PD Dr. med. Hilmar Kühl, and Prof. Dr. rer. nat. Karl-Heinz Jöckel in issue 38/2015"]In: Deutsches Ärzteblatt international Jg. 113 (2016) Nr. 17, S. 297 - 298Online Volltext: dx.doi.org/ (Open Access)
-
Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances : Data of the FIRE-1 studyIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. Suppl. 4, S. 562Online Volltext: dx.doi.org/
-
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trialsIn: Annals of Oncology Jg. 27 (2016) Nr. 11, S. 2103 - 2110Online Volltext: dx.doi.org/ (Open Access)
-
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 3, S. 380 - 390Online Volltext: dx.doi.org/ (Open Access)
-
Früherkennung von Lungenkrebs : Low-dose-Computertomographie-ScreeningIn: Der Onkologe Jg. 22 (2016) Nr. 8, S. 568 - 577Online Volltext: dx.doi.org/
-
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIOIn: The Lancet Oncology Jg. 17 (2016) Nr. 12, S. 1697 - 1708Online Volltext: dx.doi.org/
-
IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancerIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 2, S. ii141 - ii142Online Volltext: dx.doi.org/
-
Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLCIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 10 Supplement, S. 210 - S. 211Online Volltext: dx.doi.org/ (Open Access)
-
Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) : 138PDIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. Suppl. 4, S. 116 - 117Online Volltext: dx.doi.org/
-
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinibIn: OncoTarget Jg. 7 (2016) Nr. 27, S. 41390 - 41403Online Volltext: dx.doi.org/ (Open Access)
-
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoIn: Annals of Oncology Jg. 27 (2016) Nr. 6, S. 1172 - 1173Online Volltext: dx.doi.org/
-
Small cell neuroendocrine carcinoma of the right eye : A case reportIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 189 - 189
-
developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, 360O_PROnline Volltext: dx.doi.org/
-
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyIn: Journal of Thoracic Disease Jg. 7 (2015) Nr. 3, S. 264 - 272Online Volltext: dx.doi.org/
-
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years : Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)In: Annals of Oncology Jg. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, S. 136 - 137
-
Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)In: Annals of Oncology Jg. 26 (2015) Nr. S 1, S. i33 - i34Online Volltext: dx.doi.org/
-
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trialsIn: The Lancet Oncology Jg. 16 (2015) Nr. 2, S. 141 - 151Online Volltext: dx.doi.org/
-
Alternative tumor suppressor mechanisms in lung carcinomas - modulation of senescence by growth factor-induced signalingIn: Cancer Research Jg. 75 (2015) Nr. 15 Suppl., S. 1033Online Volltext: dx.doi.org/
-
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphomaIn: Blood Jg. 126 (2015) Nr. 10, S. 1257 - 1258Online Volltext: dx.doi.org/
-
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) : Primary endpoint and subgroup analysis of the CEBIFOX trialIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15 Suppl., S. 3568Online Volltext: dx.doi.org/
-
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6In: The Lancet Oncology Jg. 16 (2015) Nr. 7, S. 830 - 838Online Volltext: dx.doi.org/
-
Comprehensive genomic profiles of small cell lung cancerIn: Nature Jg. 524 (2015) Nr. 7563, S. 47 - 53Online Volltext: dx.doi.org/ (Open Access)
-
Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 141 (2015) Nr. 1, S. 87 - 92Online Volltext: dx.doi.org/
-
Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancerIn: Cancer Research Jg. 75 (2015) Nr. 15 Suppl., S. CT136Online Volltext: dx.doi.org/
-
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasIn: Lung Cancer Jg. 88 (2015) Nr. 1, S. 34 - 41Online Volltext: dx.doi.org/
-
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)In: Annals of Oncology Jg. 26 (2015) Nr. S 6, S. vi73 - vi89Online Volltext: dx.doi.org/
-
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 8073Online Volltext: dx.doi.org/ Online Volltext
-
Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal TumorIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0120531Online Volltext: dx.doi.org/ (Open Access)
-
Lungenkrebsscreening mit Low-Dose-Computertomographie in Deutschland : Hochrechnung der Kennzahlen des National Lung Screening TrialIn: Deutsches Ärzteblatt international Jg. 112 (2015) Nr. 38, S. 637 - 644Online Volltext: dx.doi.org/ (Open Access)
-
Molecular dissection of the impact of frequent genetic alterations on the response of head and neck cancers to anti-epidermal growth factor receptor-directed therapiesIn: Oral Oncology Jg. 51 (2015) Nr. 5, S. e39Online Volltext: dx.doi.org/
-
Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)In: Annals of Oncology Jg. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, S. 136Online Volltext: dx.doi.org/
-
Phase I study of the PI3K alpha inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancerIn: Cancer Research Jg. 75 (2015) Nr. S 9, S. 9 - 13Online Volltext: dx.doi.org/
-
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 35, S. 4194 - 4201Online Volltext: dx.doi.org/
-
Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 10518Online Volltext: dx.doi.org/ Online Volltext
-
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factorsIn: BMC Cancer Jg. 15 (2015) Nr. 1, S. 363Online Volltext: dx.doi.org/ (Open Access)
-
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF CohortIn: Annals of Oncology Jg. 26 (2015) Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, S. i61Online Volltext: dx.doi.org/
-
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF CohortIn: Journal of Thoracic Oncology Jg. 10 (2015) Nr. 10, S. 1451 - 1457Online Volltext: dx.doi.org/ (Open Access)
-
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsIn: The New England Journal of Medicine Jg. 373 (2015) Nr. 8, S. 726 - 736Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung CancerIn: The Journal of Biological Chemistry (JBC) Jg. 289 (2014) Nr. 8, S. 5208 - 5216Online Volltext: dx.doi.org/
-
Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy : A Case Report and Review of the LiteratureIn: American Journal of Perinatology Reports Jg. 4 (2014) Nr. 1, S. 017 - 022Online Volltext: dx.doi.org/ (Open Access)
-
Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer PatientsIn: Clinical Lung Cancer Jg. 15 (2014) Nr. 5, S. 320 - 330.e3Online Volltext: dx.doi.org/
-
Brain metastases in sarcoma patients : Incidence and outcomeIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 10591Online Volltext: dx.doi.org/
-
Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK plus) non small cell lung cancer (NSCLO) and brain metastases (BM) in the ascend-1 trialIn: Neuro-Oncology Jg. 16 (2014) Nr. Suppl. 5, S. v39Online Volltext: dx.doi.org/
-
Ceritinib in ALK-Rearranged Non–Small-Cell Lung CancerIn: The New England Journal of Medicine Jg. 370 (2014) Nr. 13, S. 1189 - 1197Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC : Subgroup analysis of the ASCEND-1 trialIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 8078Online Volltext: dx.doi.org/
-
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) : Results of the ASCEND-1 trialIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 8003Online Volltext: dx.doi.org/
-
Continuation of afatinib beyond progression : Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigators choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressedIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 8019Online Volltext: dx.doi.org/
-
Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung CancerIn: American Journal of Clinical Pathology Jg. 142 (2014) Nr. Suppl. 1, S. A182Online Volltext: dx.doi.org/
-
Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancerIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. e22032Online Volltext: dx.doi.org/
-
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer PatientsIn: PLoS ONE Jg. 9 (2014) Nr. 1, e85350Online Volltext: dx.doi.org/ (Open Access)
-
Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistanceIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 10555Online Volltext: dx.doi.org/
-
Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and ErlotinibIn: The Oncologist Jg. 19 (2014) Nr. 10, S. 1100 - 1109Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunityIn: Cell Death and Disease Jg. 5 (2014) Nr. 12, 1568Online Volltext: dx.doi.org/ (Open Access)
-
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyIn: Cell Death and Disease Jg. 5 (2014) Nr. 2, e1091Online Volltext: dx.doi.org/ (Open Access)
-
LUX-Lung 3: redundancy, toxicity or a major step forward? : Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancerIn: Future Oncology Jg. 10 (2014) Nr. 4, S. 533 - 540Online Volltext: dx.doi.org/
-
Molekulare Labordiagnostik bei gastrointestinalen TumorerkrankungenIn: Der Gastroenterologe Jg. 9 (2014) Nr. 2, S. 127 - 137Online Volltext: dx.doi.org/
-
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) : Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] andIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 8004Online Volltext: dx.doi.org/
-
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumorsIn: Cancer Research Jg. 74 (2014) Nr. 19 Suppl.,Online Volltext: dx.doi.org/
-
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancerIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 3514Online Volltext: dx.doi.org/
-
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancerIn: European Journal of Cancer (EJC) Jg. 50 (2014) Nr. Suppl. 6, S. 199Online Volltext: dx.doi.org/
-
Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 7510Online Volltext: dx.doi.org/
-
Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsIn: British Journal of Cancer (BJC) Jg. 110 (2014) Nr. 5, S. 1155 - 1162Online Volltext: dx.doi.org/ (Open Access)
-
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 621Online Volltext: dx.doi.org/
-
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 627Online Volltext: dx.doi.org/
-
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junctionIn: Cancer Immunology, Immunotherapy Jg. 63 (2014) Nr. 12, S. 1273 - 1284Online Volltext: dx.doi.org/
-
Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancerIn: Journal of Thoracic Oncology Jg. 9 (2014) Nr. 9, S. 1294 - 1304Online Volltext: dx.doi.org/
-
Successful resuscitation of a patient with ventricular fibrillation due to hypomagnesemia under cetuximab therapyIn: TumorDiagnostik & Therapie Jg. 35 (2014) Nr. 1, S. 25 - 27Online Volltext: dx.doi.org/
-
Targeted therapies in gastroesophageal cancerIn: European Journal of Cancer (EJC) Jg. 50 (2014) Nr. 7, S. 1247 - 1258Online Volltext: dx.doi.org/
-
Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 8034Online Volltext: dx.doi.org/
-
Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumorsIn: Cancer Research Jg. 74 (2014) Nr. 19 Suppl.,Online Volltext: dx.doi.org/
-
Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancerIn: Cancer Research Jg. 74 (2014) Nr. 16, S. 4258 - 4269Online Volltext: dx.doi.org/
-
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma : A ReviewIn: Oncology Research and Treatment Jg. 36 (2013) Nr. 9, S. 510 - 518Online Volltext: dx.doi.org/
-
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) : An interim analysis of the CEBIFOX trialIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. e14502Online Volltext: dx.doi.org/
-
Clinical perspective of afatinib in non-small cell lung cancerIn: Lung Cancer Jg. 81 (2013) Nr. 2, S. 155 - 161Online Volltext: dx.doi.org/
-
Comparison of the Sixth and the Seventh Editions of the UICC Classification for Perihilar CholangiocarcinomaIn: Annals of Surgical Oncology Jg. 20 (2013) Nr. 1, S. 277 - 284Online Volltext: dx.doi.org/
-
Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions : Initial resultsIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 185 (2013) Nr. 11, S. 1056 - 1062Online Volltext: dx.doi.org/
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research Jg. 73 (2013) Nr. 12, S. 3661 - 3670Online Volltext: dx.doi.org/
-
Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinibIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. Suppl. 2, S. 190Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 15, S. 3076 - 3082Online Volltext: dx.doi.org/
-
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatmentIn: British Journal of Cancer (BJC) Jg. 109 (2013) Nr. 5, S. 1223 - 1229Online Volltext: dx.doi.org/ (Open Access)
-
Free soluble HLA-G molecules but not exosome-derived soluble HLA-G molecules are of prognostic relevance in lung cancer patientsIn: Tissue Antigens Jg. 81 (2013) Nr. 5, S. 282 - 283Online Volltext: dx.doi.org/
-
IAP gene alterations and therapeutic modulation of IAPs by Smac mimetics in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 245 - 246 -
LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutationsIn: Lung Cancer Jg. 79 (2013) Nr. Suppl. 1, S. 11Online Volltext: dx.doi.org/
-
Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockadeIn: Oncogene Jg. 32 (2013) Nr. 23, S. 2873 - 2881Online Volltext: dx.doi.org/
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 27, S. 3327 - 3334Online Volltext: dx.doi.org/
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment Jg. 142 (2013) Nr. 1, S. 81 - 88Online Volltext: dx.doi.org/
-
Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific P13K inhibitor in combination with fulvestrant : Results from a phase I studyIn: Cancer Research Jg. 73 (2013) Nr. Suppl. 24,Online Volltext: dx.doi.org/
-
Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719 : Results from the first-in-human studyIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 2531Online Volltext: dx.doi.org/
-
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomasIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 4080Online Volltext: dx.doi.org/
-
Secondary KIT mutations negatively impact cell growth in a novel isogenic model of imatinib-resistance in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 178 - 179 -
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 1, S. 19 - 30Online Volltext: dx.doi.org/
-
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant CancersIn: ACS Chemical Biology Jg. 8 (2013) Nr. 9, S. 1869 - 1875Online Volltext: dx.doi.org/
-
Symptom control and quality of life in lux-lung 3 : A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 27, S. 3342 - 3350Online Volltext: dx.doi.org/
-
Trabectedin in metastatic soft tissue sarcomas : Role of pretreatment and ageIn: International Journal of Oncology Jg. 43 (2013) Nr. 1, S. 23 - 28Online Volltext: dx.doi.org/
-
Tumor laterality influences the prognostic impact of Bcl-2 expression in curatively resected NSCLC patientsIn: European Respiratory Journal (ERJ) Jg. 42 (2013) Nr. Suppl. 57,
-
Ärztliche Behandlung von an Krebs Erkrankten : Alles ganz anders?In: Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (ZEFQ) Jg. 107 (2013) Nr. 2, S. 116 - 119Online Volltext: dx.doi.org/
-
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerIn: Breast Cancer Research and Treatment Jg. 134 (2012) Nr. 3, S. 1149 - 1159Online Volltext: dx.doi.org/ (Open Access)
-
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancerIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 410 - 411
-
Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy : Interim subset analysis from a phase III trialIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15,
-
Antikörper zur adoptiven Immuntherapie solider TumorenIn: Der Onkologe Jg. 18 (2012) Nr. 9, S. 757 - 769Online Volltext: dx.doi.org/
-
Chemotherapy in resectable sarcomas with complex karyotypes - a single center retrospective analysisIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 150 - 150
-
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 4, S. 766 - 767Online Volltext: dx.doi.org/ (Open Access)
-
Developments in targeted therapy : FGFR1 inhibition in lung cancerIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. Suppl. 6, S. 23
-
Distribution pattern of metastases and their associations with survival of malignant pleural mesothelioma patients undergoing different treatment modalitiesIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 140
-
Early clinical evaluation of FGFR1 inhibition in lung cancer : Preliminary results of a phase I study in FGFR1 amplified lung cancer patients treated with BGJ398, a pan FGFR inhibitorIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 137
-
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, S. 1440 - 1448Online Volltext: dx.doi.org/ (Open Access)
-
Growth patterns of lung metastases from sarcoma : prognostic and surgical implications from histologyIn: Interactive Cardiovascular and Thoracic Surgery Jg. 15 (2012) Nr. 4, S. 612 - 617Online Volltext: dx.doi.org/
-
Impact of HPV status on the response of head and neck cancers to the anti-EGFR antibody cetuximabIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 193 - 193
-
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 138 (2012) Nr. 8, S. 1385 - 1394Online Volltext: dx.doi.org/
-
Inhibitors of Apoptosis Proteins (IAPs) in gastrointestinal stromal tumors - a therapeutic target?In: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 249
-
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monoIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. 7557
-
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigators choice chemotherapy following progression on afatinib monotIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15,
-
Intimal sarcoma of the pulmonary artery with unusual findings : a case reportIn: Clinical Research in Cardiology Jg. 101 (2012) Nr. 5, S. 397 - 401Online Volltext: dx.doi.org/
-
Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based ChemotherapyIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, Suppl. 4, S. S211 - S212
-
LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutationsIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 402
-
LUX-Lung 3 : A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. LBA7500Online Volltext: dx.doi.org/
-
LUX-Lung 3 : A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)In: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, Suppl. 4, S. 203
-
Lux-Lung 3 : a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR-activating mutationsIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, Suppl. 3, S. 161
-
Lux-Lung 3 : A randomized, open-label, phase III study of afatinib vs. pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR activating mutationsIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 7, S. 102
-
Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutationIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 11, S. 8
-
Molekular zielgerichtete Tumortherapien : aktueller Stand und künftige EntwicklungenIn: TumorDiagnostik & Therapie Jg. 33 (2012) Nr. 6, S. 311 - 314Online Volltext: dx.doi.org/
-
P53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsIn: PLoS ONE Jg. 7 (2012) Nr. 5,Online Volltext: dx.doi.org/ (Open Access)
-
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 138 (2012) Nr. 4, S. 545 - 554Online Volltext: dx.doi.org/
-
Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid TumorsIn: European Journal of Cancer (EJC) Jg. 48 (2012) Nr. Suppl. 6, S. 112Online Volltext: dx.doi.org/
-
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. 10032
-
Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumorsIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 157 - 158
-
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancerIn: Annals of Oncology Jg. 23 (2012) Nr. 9, S. 2306 - 2313Online Volltext: dx.doi.org/ (Open Access)
-
Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcomas progressing after multiple pretreatmentsIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15,
-
Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) expression in metastatic non-small cell lung cancer patients treated with pemetrexed-based chemotherapyIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 34
-
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesIn: Blood Cancer Journal Jg. 2 (2012) Nr. 3, S. e60Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the anti-apoptotic protein BCL-XL to overcome RAS mediated resistance to anti-EGFR antibody therapy in colorectal cancerIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 253
-
Trends in survival of patients with metastatic breast cancerIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 187
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 204 - 204
-
Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerIn: British Journal of Cancer (BJC) Jg. 107 (2012) Nr. 5, S. 823 - 830Online Volltext: dx.doi.org/ (Open Access)
-
Angiosarcomas of the adulthood - a large single center analysisIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 254 - 254
-
Comparison of PIK3CA Hot Spot Mutations in the Primary Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-Expression in Circulating Tumor Cells of Metastatic Breast Cancer Patients under Sequential Palliative TherapyIn: Cancer Research Jg. 71 (2011) Nr. Suppl. 24,Online Volltext: dx.doi.org/
-
Development of xenograft-based in vivo models of gastrointestinal stromal tumorsIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 253 - 253
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW Jg. 136 (2011) Nr. 1-2, S. 39 - 44Online Volltext: dx.doi.org/
-
Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancerIn: Breast Cancer Research and Treatment Jg. 125 (2011) Nr. 3, S. 637 - 646Online Volltext: dx.doi.org/
-
Evaluation of Betav-Tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancerIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. 1078
-
Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 4, S. 14
-
Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung CancerIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 12, S. 1976 - 1983Online Volltext: dx.doi.org/ (Open Access)
-
Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S1052 - S1053
-
Inhibition of the Ras/Raf/MAPK-pathway in GIST : Therapeutic potential?In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 235 - 235
-
Multivisceral systemic metastases from an intracranial anaplastic meningioma : A case report and review of literatureIn: Clinical Neurology and Neurosurgery Jg. 113 (2011) Nr. 7, S. 592 - 595Online Volltext: dx.doi.org/
-
Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms : Der Pfeil des Wilhelm Tell?In: Der Onkologe Jg. 17 (2011) Nr. 8, S. 702 - 708Online Volltext: dx.doi.org/
-
Pharmacological Inhibition of NF-k and PLK-1 to the Opening of the RAS-mediated Resistance to anti-EGFR Antibody therapies in Colorectal cancer *In: Der Internist Jg. 52 (2011) Nr. 6, S. 726 - 726
-
Polo-like kinase 1 inhibitors in mono- and combination therapies : A new strategy for treating malignanciesIn: Expert Review of Anticancer Therapy Jg. 11 (2011) Nr. 7, S. 1117 - 1132Online Volltext: dx.doi.org/
-
Predictive value of thymidylate synthase and Folypoly-Glutamate Synthease for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S1092 - S1093
-
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7024Online Volltext: dx.doi.org/
-
Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RASIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. Suppl. 4, S. 440Online Volltext: dx.doi.org/
-
Solitärer Lungenrundherd - Weitere Abklärung erforderlich?In: TumorDiagnostik & Therapie Jg. 32 (2011) Nr. 1, S. 33 - 37Online Volltext: dx.doi.org/
-
The BH3-mimetic ABT-263 enhances the apoptotic response of GIST cells to KIT-inhibitory treatmentsIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 254
-
Trabectedin in heavily pretreated and elderly metastatic soft tissue sarcomas - a single center experienceIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 237 - 237
-
Treatable Bortezomib-related peripheral neuropathy in multiple myelomaIn: Journal of the Peripheral Nervous System Jg. 16 (2011) Nr. Suppl. 3, S. 68
-
Very Late and Isolated Leptomeningeal Relapse of a Pulmonary Adenocarcinoma Presenting as DementiaIn: Onkologie Jg. 34 (2011) Nr. 6, S. 316 - 320Online Volltext: dx.doi.org/
-
Zielgerichtete Therapie für Patienten mit SchilddrüsenkarzinomIn: TumorDiagnostik & Therapie Jg. 32 (2011) Nr. 5, S. 269 - 276Online Volltext: dx.doi.org/
-
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerIn: Annals of Oncology Jg. 21 (2010) Nr. 2, S. 275 - 282Online Volltext: dx.doi.org/
-
BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapiesIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 1065Online Volltext: dx.doi.org/
-
ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast CancerIn: Clinical Cancer Research Jg. 16 (2010) Nr. 2, S. 451 - 460Online Volltext: dx.doi.org/
-
Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimeticIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 69 - 70Online Volltext: dx.doi.org/
-
Individualisierte Therapie für Patienten mit fortgeschrittenen LungenkarzinomenIn: TumorDiagnostik & Therapie Jg. 31 (2010) Nr. 2, S. 79 - 87Online Volltext: dx.doi.org/
-
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM)In: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 10047Online Volltext: dx.doi.org/
-
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapyIn: Neoplasia: An International Journal for Oncology Research Jg. 12 (2010) Nr. 8, S. 628 - 636Online Volltext: dx.doi.org/ (Open Access)
-
Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancerIn: Inflammatory Bowel Diseases Jg. 16 (2010) Nr. 4, S. 559 - 567Online Volltext: dx.doi.org/
-
Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patientsIn: Human Immunology Jg. 71 (2010) Nr. 5, S. 489 - 495Online Volltext: dx.doi.org/
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I studyIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 12, S. 2085 - 2093Online Volltext: dx.doi.org/
-
Targeted Therapies in der Behandlung solider und hämatologischer NeoplasienIn: TumorDiagnostik & Therapie Jg. 31 (2010) Nr. 3, S. 133 - 142Online Volltext: dx.doi.org/
-
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy : Results from an open-label, randomized phase ii clinical trialIn: Journal of Thoracic Oncology Jg. 5 (2010) Nr. 7, S. 1060 - 1067Online Volltext: dx.doi.org/ (Open Access)
-
Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell TumoursIn: European Urology Jg. 57 (2010) Nr. 4, S. 679 - 687Online Volltext: dx.doi.org/
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research Jg. 69 (2009) Nr. 17, S. 6941 - 6950Online Volltext: dx.doi.org/ (Open Access)
-
RASSF1A mediates p21Cip1/Waf1- dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of AktIn: Cancer Research Jg. 69 (2009) S. 1748 - 1757
-
Targeting AKT signaling sensitizes cancer to cellular immunotherapyIn: Cancer Research Jg. 68 (2008) S. 3899 - 3906
-
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosisIn: Blood Jg. 112 (2008) Nr. 8, S. 3312 - 3321Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.In: Science Jg. 5891 (2008) Nr. 321, S. 974 - 977
-
pp32/PHAPI determines the apoptosis response of non-small-cell lung cancerIn: Cell Death and Differentiation Jg. 15 (2008) S. 161 - 170
-
Kleinzelliges LungenkarzinomIn: Die Onkologie Jg. 30 (2024) Nr. 9, S. 776 - 779Online Volltext: dx.doi.org/ (Open Access)
-
Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?In: European Journal of Cancer (EJC) Jg. 145 (2021) S. 255 - 257Online Volltext: dx.doi.org/
-
Inhibiting fibroblast growth factor receptors in cancer – the next generationIn: Annals of Oncology Jg. 31 (2020) Nr. 10, S. 1285 - 1286Online Volltext: dx.doi.org/ (Open Access)
-
Tumorimmunologie : Beginn einer neuen Ära?In: Der Onkologe Jg. 18 (2012) S. 754 - 756Online Volltext: dx.doi.org/
-
Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancerIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 2513Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trialIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 8515Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trialIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 1088Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations : Pooled analysis of RAGNAR and LUC2001 studiesIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 4121Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial : Exploratory cohortIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 3119Online Volltext: dx.doi.org/ (Open Access)
-
Homologous recombination repair (HRR) deficiency in biliary tract cancers : Clinical implications in subsequent therapy lines and correlation with platinum sensitivity
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology Jg. 35 (2024) Nr. Supplement 1, S. S127Online Volltext: dx.doi.org/ -
Predicting persistent fever in patients with cancer using machine learningIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 16_suppl, e13552Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S415Online Volltext: dx.doi.org/ (Open Access) -
68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S265Online Volltext: dx.doi.org/ (Open Access) -
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer PatientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 - S489Online Volltext: dx.doi.org/
-
68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P165
-
Biomarker subgroup analyses of the Phase III study CodeBreaK 200 comparing sotorasib to docetaxel in pretreated patients with KRAS G12C-mutated non-small cell lung cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 148 - 149Online Volltext: dx.doi.org/ (Open Access) -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P714
-
HER2-low as potential prognostic biomarker in patients (pts) with metastatic or recurrent Gastric Cancer (GC) or esophageal-gastric junction (AEG) adenocarcinoma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 117 - 118Online Volltext: dx.doi.org/ (Open Access) -
KontRASt-01 update : safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 147 - 148Online Volltext: dx.doi.org/ (Open Access) -
Kreuzvalidierte Prognoseparameter C-reaktives Protein und Blutbild-Parameter im Verlauf der kurativ intendierten Radiochemotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) im Stadium IIIA-CIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S100 - S101Online Volltext: dx.doi.org/ (Open Access)
-
Langzeitüberleben und konkurrierende Risiken von Patienten einer randomisierten Studie zur defnitiven vs. neoadjuvanten Radiochemotherapie + Resektion mit einem nach der Induktion resektablen NSCLC im Stadium IIIIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S7 - S8Online Volltext: dx.doi.org/ (Open Access)
-
Long-term Survival in Patients with oligometastatic Lung Cancer (cT4 or cN2-3, cM1a-c) after thoracic Chemoradiation, Metastasis-directed and Systemic Therapy compared with the Outcome in locally advanced Lung Cancer (cT4 or cN2-3, cM0)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S101 - S102Online Volltext: dx.doi.org/
-
Molecular characterization of biliary tract cancer at a single comprehensive cancer center focusing on DNA damage repair genes
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 62Online Volltext: dx.doi.org/ (Open Access) -
RCT to Test the Efficacy of an EEG Neurofeedback Intervention in Cancer Patients and Cancer Survivors
Deutscher Kongress für Psychosomatische Medizin und Psychotherapie, 03.-05.05.2023, Berlin,In: Zeitschrift für Psychosomatische Medizin und Psychotherapie Jg. 69 (2023) Nr. 2, S. 148 - 149Online Volltext: dx.doi.org/ -
68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S107Online Volltext: dx.doi.org/ (Open Access) -
A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1404Online Volltext: dx.doi.org/ (Open Access) -
Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLCIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. 611Online Volltext: dx.doi.org/
-
Entitäten-unabhängige Sicherheit und Wirksamkeit von Erdafitinib bei Patienten mit fortgeschrittenen soliden Tumoren mit präspezifizierten genomischen FGFR- Aberrationen (RAGNAR Interimanalyse)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 27 - 28Online Volltext: dx.doi.org/ (Open Access) -
Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma CellsIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. 118Online Volltext: dx.doi.org/
-
KontRASt-01 : eine Phase Ib/II Dosiseskalationsstudie von JDQ443 in Patienten mit fortgeschrittenen, KRAS G12C-mutierten soliden Tumoren
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 07. bis 10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 29Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLCIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. 65Online Volltext: dx.doi.org/
-
MO29-3 A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib : Focus on Asian patients
The 19th Annual Meeting of JSMO (Japanese Society of Medical Oncology), 17.–19.02.2022, Kyoto,In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 6: 2022 the Japanese Society of Medical Oncology Annual Meeting 17–19 February 2022, Kyoto, Japan, S. 500Online Volltext: dx.doi.org/ (Open Access) -
Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung CancerIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. 203Online Volltext: dx.doi.org/
-
Profil der multizentrischen Kohorte der Klinischen Kommunicationsplattform des Deutschen Konsortiums für Translationale Krebsforschung (DKTK)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 13Online Volltext: dx.doi.org/ (Open Access) -
Robuste und lang-andauernde Wirksamkeit der Durvalumab-Konsolidierung bei NSCLC im Stadium III nach Induktionschemotherapie und definitiver Radiochemotherapie : Fokus auf Behandlungsauswahl und prognostische Faktoren
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S15Online Volltext: dx.doi.org/ (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 - S1232Online Volltext: dx.doi.org/ (Open Access) -
Second interim analysis of INFINITY : A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practiceIn: Annals of Oncology Jg. 33 (2022) S. 575 - S576Online Volltext: dx.doi.org/
-
Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation : CodeBreaK 200 phase III study
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1417 - S1418Online Volltext: dx.doi.org/ (Open Access) -
Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C InhibitionIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. S586 - S587Online Volltext: dx.doi.org/
-
Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR : Interim analysis (IA) resultsIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 3007Online Volltext: dx.doi.org/ (Open Access)
-
Zweite Interimsanalyse zu INFINITY : ein Register zur Entscheidungsfindung in der Biomarker-basierten Präzisionsonkologie und deren klinische Bedeutung
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
SITC 36th Anniversary Annual Meeting (SITC 2021), 10-14 November 2021, Washington & virtually,In: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. Suppl. 2, S. A536 - A536Online Volltext: dx.doi.org/ (Open Access) -
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_suppl, S. TPS2658Online Volltext: dx.doi.org/ (Open Access) -
A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations
2021 Gastrointestinal Cancers Symposium, 15-17 January 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 3, Supplement, S. TPS480Online Volltext: dx.doi.org/ (Open Access) -
Afatinib for the treatment of NSCLC with uncommon EGFR mutations : An updated database of 1023 casesIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 965Online Volltext: dx.doi.org/ (Open Access)
-
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors : Update from the ARROW trialIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 3079 - 3079Online Volltext: dx.doi.org/
-
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors
2021 Gastrointestinal Cancers Symposium, 15-17 January 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 3, Supplement, S. 467 - 467Online Volltext: dx.doi.org/ (Open Access) -
EBUS-TBNA and [F-18] FDG-PET/CT for precise Target Volume Definition prior to Chemoradiotherapy : Lymphonodular Spreading Patterns in Stage III NSCLCIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 142
-
Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC) : Secondary and exploratory results of phase 3b RIBECCA studyIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 467 - S468Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world settingIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 812Online Volltext: dx.doi.org/ (Open Access)
-
Influence of external and self-assessment in symptom burden of cancer patients in a palliative care outpatient clinic of a Comprehensive Cancer Center
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 92Online Volltext: dx.doi.org/ (Open Access) -
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumorsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290
-
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancerIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9003 - 9003Online Volltext: dx.doi.org/
-
Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinibIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 4081 - 4081Online Volltext: dx.doi.org/
-
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 3566 - 3566Online Volltext: dx.doi.org/
-
Re-Irradiation of cerebral Metastases after prophylactic Brain Skull irradiation in small-cell neuroendocrine Lung Cancer (SCLC)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 176
-
Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC : first disclosure of the CodeBreaK 100 primary analysisIn: Pneumologie Jg. 75 (2021) Nr. Suppl. 1, 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Leipzig digital, 02.–05.06.2021, S. S38Online Volltext: dx.doi.org/
-
Systemic inflammatory response parameters as prognostic markers in patients with recurrent or metastatic head and neck cancer treated with immunotherapy
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 58Online Volltext: dx.doi.org/ (Open Access) -
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research Jg. 80 (2020) Nr. 16: Supplement, S. CT301Online Volltext: dx.doi.org/ -
Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Supplement 6, S. S1396Online Volltext: dx.doi.org/ (Open Access) -
Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutationsIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S860 - S861Online Volltext: dx.doi.org/ (Open Access)
-
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.In: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 109Online Volltext: dx.doi.org/
-
First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 251 - 252Online Volltext: dx.doi.org/ (Open Access) -
Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 159Online Volltext: dx.doi.org/ (Open Access) -
Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer : The RAMTAS trial of the German AIOIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S427 - S428Online Volltext: dx.doi.org/ (Open Access)
-
Lymphknoten-Staging von lokal fortgeschrittenen, nicht kleinzelligen Lungenkarzinomen (NSCLC) : Wert von [18F] FDG-PET/CT und EBUS/TBNA zur Festlegung des Zielvolumens bei definitiver Radiotherapie in kurativer Intention
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S143Online Volltext: dx.doi.org/ (Open Access) -
Optimierung prognostischer Modelle für das Überleben von Patienten mit lokal fortgeschrittenen kleinzelligen Lungenkarzinomen nach definitiver Radiochemotherapie mittels künstlicher Intelligenz
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S57 - S58Online Volltext: dx.doi.org/ (Open Access) -
Palliative knowledge and self-efficacy expectation of residents before and after palliative care unit rotation - A national study project
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 210Online Volltext: dx.doi.org/ (Open Access) -
Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 137Online Volltext: dx.doi.org/ (Open Access) -
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterationsIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 3640Online Volltext: dx.doi.org/
-
Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterationsIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. 502 - S503Online Volltext: dx.doi.org/ (Open Access)
-
RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the third interim analysisIn: Cancer Research Jg. 80 (2020) Nr. 4,Online Volltext: dx.doi.org/
-
Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 141 - 142Online Volltext: dx.doi.org/ (Open Access) -
Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Supplement 6, S. S1413 - S1414Online Volltext: dx.doi.org/ (Open Access) -
Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)In: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S1084Online Volltext: dx.doi.org/ (Open Access)
-
The impact of needle choice on molecular analysis of ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in NSCLCIn: European Respiratory Journal (ERJ) Jg. 56 (2020) Nr. Suppl. 64,Online Volltext: dx.doi.org/
-
A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor HeterogeneityIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S571 - S572Online Volltext: dx.doi.org/ (Open Access)
-
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients : The RAMTAS trial of the German AIO (KRK-0316)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. TPS3617 - TPS3617Online Volltext: dx.doi.org/
-
Advanced Age and High Modified Glasgow Prognostic Score Are Associated with Increased Complications After PneumonectomyIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S677Online Volltext: dx.doi.org/ (Open Access)
-
Barriers and motivation of physical activitiy (PA) in patients with cancer related fatigue (CRF)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 165Online Volltext: dx.doi.org/ (Open Access) -
EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerabilityIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. e20577 - e20577Online Volltext: dx.doi.org/
-
Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levelsIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. e20661 - e20661Online Volltext: dx.doi.org/
-
Integration of immune checkpoint inhibitors in the treatment of early stage lung cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 13Online Volltext: dx.doi.org/ (Open Access) -
MA17.07 Identification of AHR as a Novel Regulator of Lung Cancer MetastasisIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S319Online Volltext: dx.doi.org/ (Open Access)
-
P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC : Activity in Patients with Brain Metastases, and Impact on CNS Progression/SpreadIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, S. 855Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer : Secondary Analysis of a Randomized Phase 3 Trial
61st Annual Meeting of the American Society for Radiation Oncology ; September 15-18, 2019, Chicago, IL, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 105 (2019) Nr. 1, Supplement, S. S146 - S147Online Volltext: dx.doi.org/ (Open Access) -
RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis.In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 1061 - 1061Online Volltext: dx.doi.org/
-
Adverse events self-reported by patients with advanced non-small cell lung cancer treated with osimertinib or chemotherapy in the AURA3 trial
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 111Online Volltext: dx.doi.org/ (Open Access) -
Afatinib for patients with EGFR mutation-positive (EGFRm plus ) NSCLC : Activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread
COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, 13–15 November 2018, Perth Australia,In: Asia-Pacific Journal of Clinical Oncology Jg. 14 (2018) Nr. Suppl. 7, S. 159 - 160Online Volltext: dx.doi.org/ -
Central Nervous System or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients Receiving Afatinib in LUX-Lung 3, 6, and 7
Konferenz Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, New Directions in Personalised Cancer Therapy; 1–3 August 2018; Adelaide, Australia,In: Asia-Pacific Journal of Clinical Oncology Jg. 14 (2018) Nr. Supplement 3, S. 69Online Volltext: dx.doi.org/ -
Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. e15121Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 289Online Volltext: dx.doi.org/ (Open Access) -
Evaluation of prognostic markers in patients (pts) with advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (AEG) treated with systemic chemothearpy (ctx) at the West German Cancer Center
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 67Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival (LT-S) and Survivorship Program (SS-P) of Lung Cancer (LC) Patients (Pts) - B : Implications for Follow-up (F-up) and Surveillance (SV)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 109 - 110Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 108Online Volltext: dx.doi.org/ (Open Access) -
PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy : Results from the FLOT4 phase III trial of the AIOIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e24277 - e24277Online Volltext: dx.doi.org/ (Open Access)
-
Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
Geared to Learn ; USCAP 107th Annual Meeting ; March 17–23, 2018, Vancouver,In: Modern Pathology Jg. 31 (2018) Nr. Suppl. 2, S. 378Online Volltext: dx.doi.org/ (Open Access) -
RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the first interim analysisIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 1051Online Volltext: dx.doi.org/ (Open Access)
-
Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathwayIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 4513 - 4513Online Volltext: dx.doi.org/ (Open Access)
-
Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; Wien, 28. September - 2. Oktober 2018,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 321Online Volltext: dx.doi.org/ (Open Access) -
Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 6 Suppl., S. 494Online Volltext: dx.doi.org/ (Open Access)
-
Signaling network activation in colorectal cancer : p70S6K phosphorylation as a prognostic marker
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 55Online Volltext: dx.doi.org/ (Open Access) -
The prognostic impact of UDP-glucuronyltransferase 1A1*1 (UGT1A1*1) polymorphism in patients with advanced colorectal and non-colorectal cancer treated with irinotecan-based systemic chemotherapies
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 122 - 123Online Volltext: dx.doi.org/ (Open Access) -
Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancerIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung CancerIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, Suppl., S. 85
-
PD-L1 inhibition - a new therapeutic opportunity in cutaneous angiosarcoma?In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
Evaluation of prognostic markers in patients (pts) with metastatic colorectal cancer (mCRC) treated with a bevacizumab (bev) based chemotherapy (ctx) at the West German Cancer Center
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 77Online Volltext: dx.doi.org/ -
Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 307 - 308Online Volltext: dx.doi.org/
-
Evaluation of systemic inflammatory response (SIR) markers in advanced biliary tract cancer (ABTC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 5 - 6Online Volltext: dx.doi.org/ -
Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)In: Oncology Research and Treatment Jg. 38 (2015) Nr. S 5, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz, S. 4 - 5Online Volltext: dx.doi.org/
-
Experience from the ASCEND-1 trial : Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 270Online Volltext: dx.doi.org/ -
Hirnmetastasen bei Patienten mit lokal fortgeschrittenem NSCLC nach multimodaler kurativer Therapie in einem randomisierten Protokoll : prognostische Faktoren
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl. 1, S. 36 - 37Online Volltext: dx.doi.org/ -
Longitudinal analysis of the impact of the introduction of tyrosine kinase inhibitor therapy on overall survival of patients with gastrointestinal stromal tumors treated at the West German Cancer Center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 167 - 167Online Volltext: dx.doi.org/ -
Prognostische Faktoren bei Patienten mit fortgeschrittenen Pankreaskarzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
121. Kongress der Deutschen Gesellschaft für Innere Medizin ; DGIM 2015 ; 18. - 21. April 2015, Mannheim, Germany,In: Der Internist Jg. 56 (2015) Nr. Supplement 1: Abstracts zum 121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., S. 38 - 39Online Volltext: dx.doi.org/ -
Prognostische Faktoren bei Patienten mit fortgeschrittenen cholangiozellulären Karzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
121. Kongress der Deutschen Gesellschaft für Innere Medizin ; DGIM 2015 ; 18. - 21. April 2015, Mannheim, Germany,In: Der Internist Jg. 56 (2015) Nr. Supplement 1: Abstracts zum 121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., S. 37Online Volltext: dx.doi.org/ -
Rekursive Partitions-Analyse prognostischer Faktoren für das Langzeit-Überleben nach trimodaler Therapie von Patienten mit lokal fortgeschrittenem NSCLC
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl. 1, S. 23Online Volltext: dx.doi.org/ -
Solitary fibrous tumors/haemangiopericytoma : Analysis of prognostic factors of 28 patients from a high volume sarcoma center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 246Online Volltext: dx.doi.org/ -
TNM-classification for clear cell sarcomas - is it useful?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 247 - 248Online Volltext: dx.doi.org/ -
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 99 - 100Online Volltext: dx.doi.org/ -
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 226 - 227Online Volltext: dx.doi.org/ -
Circulating tumor cell composition and molecular markers in metastasized renal cell carcinoma (mRCC)
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 131Online Volltext: dx.doi.org/ -
Circulating tumor cell subgroups and outcome in patients with non-small-cell-lung-cancer receiving platinum based treatment
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 89Online Volltext: dx.doi.org/ -
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 89 - 90Online Volltext: dx.doi.org/ -
Correlation of proteomics and first-line platinum-based chemotherapy in stage NSCLC in a large single-center cohort
50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, 2014, Chicago, Illinois, USA,In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl.,Online Volltext: dx.doi.org/ -
Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C) : Results From a Multicenter Phase III Study
56th Annual Meeting of the American Society for Radiation Oncology ; 14-17 September 2014, San Francisco, CA, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 1, Supplement, S. S146 - S147Online Volltext: dx.doi.org/ -
Definitive accelerated-hyperfractionated (AHF) Chemoradiotherapy (CRT) vs. neoadjuvant AHF-CRT and Surgery (S) for Patients with operable NSCLC in Stage IIIA(N2)/IIIB after Induction Chemotherapy (IND-C) : Results of a randomized Multicentre Study
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl. 1, S. 5 - 6Online Volltext: dx.doi.org/ -
Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) : An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 5, Supplement, S. S33 - S34Online Volltext: dx.doi.org/ -
Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A) : Metastatic Non-Small Cell Lung Cancer
2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 5, Supplement, S. S41Online Volltext: dx.doi.org/ -
Impact of human papilloma virus infection on the response of head and neck cancers (HNSCC) to anti-epidermal growth factor receptor (EGFR) antibody therapy
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 76Online Volltext: dx.doi.org/ -
Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) – subgroup analyses of the CEBIFOX trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 100 - 101Online Volltext: dx.doi.org/ -
Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ)
Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 51Online Volltext: dx.doi.org/ -
Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut) : Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): Metastatic Non-Small Cell Lung Cancer
2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 5, Supplement, S. S5 - S6Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in patients (pts) with advanced cholangiocellular carcinoma (CCC) receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 122 - 123Online Volltext: dx.doi.org/ -
Prognostic factors in patients with pancreatic cancer receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ), one of the 12 Oncology Centers of Excellence in Germany
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 123 - 124Online Volltext: dx.doi.org/ -
Prognostisches Modell für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl 1, S. 17Online Volltext: dx.doi.org/ -
Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M plus ) non-small cell lung cancer (NSCLC) : Comparative analysis of Asian and non-Asian patients from two randomized trials
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 90Online Volltext: dx.doi.org/ -
Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 - 119Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 92Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 8109Online Volltext: dx.doi.org/
-
Vergleich von pCR und mediastinalem Downstaging als Surrogat- Marker für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion (Trimodalität)
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl. 1, S. 17Online Volltext: dx.doi.org/ -
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3Online Volltext: dx.doi.org/ -
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations : findings from three trials of afatinib in EGFR mutation-positive lung cancer
15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. 141Online Volltext: dx.doi.org/ -
Brain metastases in soft tissue sarcoma patients - incidence, prognosis and outcome
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 181Online Volltext: dx.doi.org/ -
Comparative safety profile of afatinib in asian and non-asian patients with EGFR mutation-positive (EGFR M plus) non-small cell lung cancer (NSCLO)
15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. 1197Online Volltext: dx.doi.org/ (Open Access) -
Effiacy of afatinib vs. chemotherapy in treatment-naive patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease
15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. S299 - S300Online Volltext: dx.doi.org/ (Open Access) -
Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 116 - 117Online Volltext: dx.doi.org/ -
Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ), one of the 11 Oncology Centers of Excellence in Germany
17 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 263Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment Jg. 36 (2013) Nr. Suppl. 7, S. 157Online Volltext: dx.doi.org/ -
Prä-therapeutische ex-vivo Reparatur Kinetiken von Cisplatin-DNA-Addukten in Zirkulierenden Tumorzellen als Platin-Resistenz Test
119. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., 06. - 09. April 2013, Wiesbaden,In: Der Internist Jg. 54 (2013) Nr. Suppl. 1, S. 95 - 96Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 30Online Volltext: dx.doi.org/
-
Targeting glucose metabolism by 2-Deoxyglucose in Gastrointestinal Stromal Tumors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 246Online Volltext: dx.doi.org/ -
Try : a phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. S914 - S915Online Volltext: dx.doi.org/ (Open Access)
-
A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumorsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. LB - 122Online Volltext: dx.doi.org/
-
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 15, Suppl., 2086Online Volltext: dx.doi.org/ -
Folylpoly-α-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC)In: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 1713Online Volltext: dx.doi.org/
-
Functional characterization of DOG1 in Gastrointestinal Stromal Tumors (GIST)In: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 1824Online Volltext: dx.doi.org/
-
Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) : a single center experience
37th ESMO Congress, 28 September - 2 October 2012, Vienna, Austria,In: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 437 - 438Online Volltext: dx.doi.org/ -
Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumorsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 3855 - 3855Online Volltext: dx.doi.org/
-
LUX-lung 3 : A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsIn: Lung Cancer Jg. 77 (2012) Nr. Suppl. 1, S. S25 - S26Online Volltext: dx.doi.org/
-
Influence of Everolimus and Pemetrexed on Thymidylate Synthase expression as well as on Proliferation and survival of non-small cell ling Cancer CellsIn: Journal of Thoracic Oncology Jg. 5 (2010) Nr. Suppl. 1, S. S56 - S57Online Volltext: dx.doi.org/
-
Metastasectomy in patients with GIST in the era of imatinib - improved survival?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 108Online Volltext: dx.doi.org/ -
Targeting NF-kappa B and PLK-1 to overcome RAS-mediated resistance to anti-EGFR antibody therapy in colorectal cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 33Online Volltext: dx.doi.org/ -
Use of ERCC1 expression levels in circulating tumor cells to predict to response to platinum-based chemotherapy in patients with non-small cell lung cancer
2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 15, Suppl., 7512 -
Apoptosis in the Physiology and Diseases of the Respiratory TractIn: Apoptosis: Physiology and Pathology / Reed, John; Green, Douglas R. 2011, S. 221 - 230Online Volltext: dx.doi.org/
-
DNA damage repair pathways in biliary tract cancer : A new target for precision medicine?
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S223Online Volltext: dx.doi.org/ (Open Access) -
Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label : Single-arm RAGNAR trial
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S898Online Volltext: dx.doi.org/ (Open Access) -
Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S273Online Volltext: dx.doi.org/ (Open Access) -
Oligometastatic non-small cell lung cancer : Impact of local and systemic treatment approaches on clinical outcome
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S828Online Volltext: dx.doi.org/ -
Immuntherapie eines Mikrosatelliten-instabilen metastasierten Talgdrüsenkarzinoms der Glandula submandibularis mit Pembrolizumab
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 230 - 231Online Volltext: dx.doi.org/ (Open Access) -
Updated ARROW data : Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1298 - S1299Online Volltext: dx.doi.org/ (Open Access) -
First interim analysis of INFINITY : A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 295Online Volltext: dx.doi.org/ (Open Access) -
Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole : Final results
San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020; San Antonio, Texas,In: Cancer Research Jg. 81 (2021) Nr. 4, Supplement, S. PS10 - 31Online Volltext: dx.doi.org/ -
Formation of multiple pneumatoceles during anti-angiogenic treatment for metastatic colorectal cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.–14. Oktober 2014, Hamburg, Germany,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 84 - 85Online Volltext: dx.doi.org/ -
Chemotherapie bei resektablen Weichteilsarkomen mit komplexem Karyotyp : eine Single-Center Analyse
The annual meeting of the German, Austrian and Swiss Society of Haematology and Oncology, 19.-23.10.2013, Stuttgart,Stuttgart (2013) -
Pre-therapeutic ex-vivo repair kinetics of cisplatin-DNA-adducts in circulating tumor cells (CTC) as platinum resistance test
11th Annual British Thoracic Oncology Group Conference, 23-25 January 2013, Dublin, Ireland,In: Lung Cancer Jg. 79 (2013) Nr. Suppl. 1, S. S2Online Volltext: dx.doi.org/ -
Decrease of circulating tumor cells associates with response to platinum-based chemotherapy in patients with non-small cell lung cancer, but not with small cell lung cancer
14th World Conference on Lung Cancer (WCLC), July 03 - 07, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S1114 -
Highly sensitive detection of somatic epidermal growth factor receptor (EGFR) gene mutations in circulating tumor cells (CTC) from patients with non-small cell lung cancer treated with cisplatin/pemetrexed or afatinib
14th World Conference on Lung Cancer, July 3 – 7, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S956 - S957Online Volltext: dx.doi.org/ -
Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)
EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’, 27-29 October 2011, Brussels, Belgium,In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 4, S. S30Online Volltext: dx.doi.org/ -
Interpatient pharmacokinetic variability of 5-FU within metastatic and adjuvant colon cancer patients : First results from the West German Cancer Center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 173Online Volltext: dx.doi.org/